Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.57 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.57 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282802 | 0.92 | RXFP1 (0.69) | RXFP1POLBAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL1719409 | 0.88 | MAPT (0.69) | RXFP1POLBMAPTALDH1A1KDM4E | |
| SCHEMBL1718201 | 0.85 | MAPT (0.67) | RXFP1POLBMAPTALDH1A1MEN1 | |
| SCHEMBL1717689 | 0.84 | HPGD (0.56) | RXFP1POLBMAPTALDH1A1MEN1 | |
| SCHEMBL4215997 | 0.84 | HPGD (0.56) | RXFP1POLBMAPTALDH1A1MEN1 | |
| SCHEMBL1718521 | 0.83 | HPGD (0.60) | RXFP1POLBMAPTALDH1A1KDM4E | |
| SCHEMBL1717682 | 0.83 | RXFP1 (0.67) | RXFP1POLBAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL1718197 | 0.83 | RXFP1 (0.69) | RXFP1POLBAPOBEC3AMAPTALDH1A1 | |
| SCHEMBL3704786 | 0.82 | RXFP1 (0.67) | RXFP1POLBAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL3060904 | 0.82 | RXFP1 (0.67) | RXFP1POLBAPOBEC3ACTDSP1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270408-A1 | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines | NOVO NORDISK A/S (DK) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270408-A1 | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines | HSD3B1, HSD11B1, SRD5A1 | RXFP1 4609/4885POLB 1055/4885APOBEC3A 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.